Abstract: As the most common, abundant and conserved internal cotranscriptional modification in eukaryotic ribonucleic acid（RNA）, N6-methyladenosine（m⁶A） modification regulates RNA shear, stability and translation, thus affecting a great variety of biological processes, such as tumor differentiation, metabolism, immunity and dry maintenance, etc. It is associated with tumorigenesis, arteriosclerosis, diabetes mellitus and cardiovascular disease. In recent years, many studies have reported that m⁶A modification is correlated closely with diabetic kidney disease（DKD）. This review explored m⁶A related genes and their regulatory mechanisms in diabetic kidney disease（DKD） and summarized drug interventions targeting m6A modification for delaying the research progress of DKD, providing important references for exploring new targets for early diagnosis and treatment of DKD.